Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

Study Identifier:
CLI-05993AA5-05
ClinicalTrials.gov Identifier:
NCT07546981
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
+ 39 0521 2791 or [email protected]
Will Be Recruiting

Study Details

Medical Condition
  • Asthma
Study Drug
  • Drug: Experimental: Participant Group CHF 5993 pMDI HFA-152a
Date
May 2026 - Oct 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the study:
  • Subjects must provide written informed consent prior to any study-related procedures;
  • Subjects must be male or female Chinese aged ≥18 and
  • ≤75 years;
  • Subjects must have a documented history of asthma for at least 1 year and asthma must have been diagnosed before the subject's age of 40;
  • Subjects must have uncontrolled asthma, receiving double therapy only on medium doses of ICS in combination with LABA at a stable dose for at least 4 weeks prior to screening;
  • Subjects must have a pre-bronchodilator FEV1 \<80% of their predicted normal value, after appropriate wash out from bronchodilators at the screening visit.
  • Subjects must have a positive response to a reversibility test at screening.
  • Subjects must have uncontrolled asthma evidenced by a score at the ACQ-7 ≥1.5 (this criterion must be met at screening and at randomisation).
Exclusion Criteria
  • Subjects meeting any of the following criteria will be excluded from study enrolment:
  • Subjects who have a history of near fatal asthma or of a past hospitalisation for status asthmaticus or severe asthma exacerbation which, in the judgement of the Investigator, may place the subject at undue risk;
  • Subjects who have undergone hospitalisation, emergency room visit or use of systemic corticosteroids for an asthma exacerbation in the 4 weeks prior to the screening visit or during the run-in period;
  • Subjects with any asthma exacerbation or respiratory tract infection in the 4 weeks prior to the screening visit or during run-in period;
  • Subjects with any change in dose, schedule or formulation of the combination ICS+LABA in the 4 weeks prior to the screening visit;
  • Subjects who have used systemic corticosteroid medication in the 4 weeks prior to screening or slow-release corticosteroids in the 12 weeks prior to screening;
  • Subjects who have a history of a diagnosis of chronic obstructive pulmonary disease (COPD) (according to the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] document), cystic fibrosis, bronchiectasis or alpha- 1 antitrypsin deficiency or any other significant lung disease which may interfere with study evaluations;
  • Subjects who are current smokers; ex-smokers with total cumulative exposure ≥10 pack-years; having stopped smoking 1 year or less prior to the screening visit;
  • Subjects who are treated with monoclonal antibodies (e.g., anti-immunoglobulin (Ig)E or anti-IgG antibodies) or biological drugs;
  • Subjects who have received an investigational drug within 2 months or six half-lives (whichever is greater) prior to the screening visit, or have been previously randomised in this study, or are currently participating in another clinical study.
Healthy Volunteers
No

Protocol Summary

This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.

Study Locations

Location
Status
Location
China-Japan Friendship Hospital
Beijing, Chaoyang District, China
Status
N/A